pancreatic cancer Archives - Career Ahead Magazine https://careeraheadonline.com/tag/pancreatic-cancer/ Shaping future professionals, entrepreneurs & students. Career Ahead magazine guides today's youth to be tomorrow's icons. Fri, 28 Aug 2026 02:02:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://careeraheadonline.com/wp-content/uploads/2025/08/career_ahead_favicon_rounded_512-75x75.png pancreatic cancer Archives - Career Ahead Magazine https://careeraheadonline.com/tag/pancreatic-cancer/ 32 32 shopengine_activated_templates \n a:1:{s:4:"shop";a:1:{s:4:"lang";a:1:{s:2:"en";a:0:{}}}} RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year https://careeraheadonline.com/revmeds-pancreatic-cancer-pill-priced-above-475k-per-year/ https://careeraheadonline.com/revmeds-pancreatic-cancer-pill-priced-above-475k-per-year/#respond Fri, 28 Aug 2026 01:49:07 +0000 https://careeraheadonline.com/revmeds-pancreatic-cancer-pill-priced-above-475k-per-year/ Explore more career insights and success stories at Career Ahead Magazine! Empowering you with trending career paths, start-up tips, and expert guidance.

Rasonque, a RAS inhibitor, targets a protein commonly mutated in pancreatic cancers, offering new hope for patients. The drug became available shortly after its approval, aiming to extend survival rates for those diagnosed with this aggressive disease. According to a report by Bloomberg, Rasonque is one of the first medicines to broadly target RAS, a protein linked to tumor growth.

This article was originally published on Career Ahead Magazine. For more actionable advice and exclusive content, visit the full post here: RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year.

Stay inspired and ahead of the curve with Career Ahead Magazine!

RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year was first posted on August 28, 2026 at 1:49 am.
©2025 "Career Ahead Magazine". Use of this feed is for personal non-commercial use only. If you are not reading this article in your feed reader, then the site is guilty of copyright infringement. Please contact me at admin@careeraheadonline.com
]]> https://careeraheadonline.com/revmeds-pancreatic-cancer-pill-priced-above-475k-per-year/feed/ 0 New Drug Approved https://careeraheadonline.com/new-drug-approved/ https://careeraheadonline.com/new-drug-approved/#respond Thu, 27 Aug 2026 13:17:46 +0000 https://careeraheadonline.com/new-drug-approved/ Explore more career insights and success stories at Career Ahead Magazine! Empowering you with trending career paths, start-up tips, and expert guidance.

The FDA's recent approval of Daraxonrasib marks a significant advancement in treatment options for pancreatic cancer, a disease known for its aggressive nature and poor prognosis.

This article was originally published on Career Ahead Magazine. For more actionable advice and exclusive content, visit the full post here: New Drug Approved.

Stay inspired and ahead of the curve with Career Ahead Magazine!

New Drug Approved was first posted on August 27, 2026 at 1:17 pm.
©2025 "Career Ahead Magazine". Use of this feed is for personal non-commercial use only. If you are not reading this article in your feed reader, then the site is guilty of copyright infringement. Please contact me at admin@careeraheadonline.com
]]> https://careeraheadonline.com/new-drug-approved/feed/ 0 Daraxonrasib Drug Set to Revolutionize Pancreatic Cancer https://careeraheadonline.com/daraxonrasib-drug-set-to-revolutionize-pancreatic-cancer/ https://careeraheadonline.com/daraxonrasib-drug-set-to-revolutionize-pancreatic-cancer/#respond Wed, 26 Aug 2026 19:17:38 +0000 https://careeraheadonline.com/daraxonrasib-drug-set-to-revolutionize-pancreatic-cancer/ Explore more career insights and success stories at Career Ahead Magazine! Empowering you with trending career paths, start-up tips, and expert guidance.

The FDA's approval of daraxonrasib marks a significant advancement in the treatment of advanced pancreatic cancer, a disease with a five-year survival rate of just 10%.

This article was originally published on Career Ahead Magazine. For more actionable advice and exclusive content, visit the full post here: Daraxonrasib Drug Set to Revolutionize Pancreatic Cancer.

Stay inspired and ahead of the curve with Career Ahead Magazine!

Daraxonrasib Drug Set to Revolutionize Pancreatic Cancer was first posted on August 26, 2026 at 7:17 pm.
©2025 "Career Ahead Magazine". Use of this feed is for personal non-commercial use only. If you are not reading this article in your feed reader, then the site is guilty of copyright infringement. Please contact me at admin@careeraheadonline.com
]]> https://careeraheadonline.com/daraxonrasib-drug-set-to-revolutionize-pancreatic-cancer/feed/ 0